Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on May 2023

Classification of products:

Status	Description
GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
RED	Red-Hospital initiation and continuation only
GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
PURPLE	To be supplied from the appropriate commissioned provider.
NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil				
2) New Requests				
Morphine sulphate orodispersible tablets (Actimorph®)	GREEN			
Aprotinin	RED			Unlicensed indication
Tezepelumab	RED			
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
4) Products considered by NICE				
TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA875: Semaglutide for managing overweight and obesity			√	Decision deferred until product is launched in UK and price is known so accurate local cost impact can be calculated.
TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable nonsmall-cell lung cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA877: Finerenone for treating chronic kidney disease in type 2 diabetes	AMB 2			The formulary will reflect the TAG – ICS is the responsible commissioner
TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Buspirone	AMB 1			

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Tranexamic acid oral preparations	GREEN			
Dapaglifozin Empaglifozin	AMB 1			

The following guidelines were presented to and approved at the May 2023 meeting of the APC:

- MS guideline

The following Green+ drug information leaflets were presented to and approved at the May 2023 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the May 2023 meeting of the APC:

- NL ADHD

Other documents presented to and approved at the May 2023 meeting of the APC:

- Chapter 1 review of joint formulary